Bone Biologics Corp

Bone Biologics Corporation develops medical devices for bone regeneration, primarily targeting spinal fusion applications. The company's lead product, NELL-1/DBM, is a recombinant human protein device designed to enhance bone formation in spinal procedures. NELL-1/DBM combines an osteopromotive recombinant protein with demineralized bone matrix to provide targeted control over bone regeneration. The company operates under a license agreement with UCLA Technology Development Group for development and commercialization rights to NELL-1 technology in spinal fusion applications.

The NELL-1 platform technology has potential applications across multiple surgical specialties including spine surgery, general orthopedics, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company's commercial focus targets spine surgeons and patients with skeletal bone defects or spine-related bone conditions requiring surgical intervention.

Based in Burlington, Massachusetts, Bone Biologics operates with a minimal employee base of two full-time staff members. The company was incorporated in Delaware and is listed on Nasdaq. As a development-stage medical device company, the organization is focused on bringing its NELL-1/DBM technology through regulatory pathways and toward clinical commercialization in the spinal fusion market.